Sex-dimorphic adverse drug reactions to immune suppressive agents in inflammatory bowel disease

Table 3 Types of adverse drug reactions to respective anti-tumor necrosis factor agents in general and stratified by sex n (%)

	Infliximab1	Infliximab23	P value2	Adalimumab	Adalimumab23	P value2
Allergic reaction	33 (15)	7 (21)	0.045	7 (7)	0	0.039
Cutaneous SE	9 (4)	5 (56)	0.492	3 (3)	3 (100)	0.064
Neurological SE	4 (1.8)	0	0.146	2 (2)	0	0.512
Dyspnoea	4 (1.8)	0	0.146	1 (1)	0	1.00
Arthralgia and/or myalgia	11 (5)	4 (45)	1.00	3 (3)	1 (33)	1.00
Injection site reactions4	NA	NA		3 (3)	1 (33)	1.00
Infectious SE	0	0		3 (3)	1 (33)	1.00
Malignancy	16 (0.4)	16 (100)	0.41	0	0
Lupus-like	1 (0.4)	0		0	0
Others5	8 (3.5)	2 (25)	0.476	0	0

¹Number of all the people treated with the medicine;

²Two-sided χ² test to compare the differences in the frequencies of specific adverse drug reaction between males and females;

³Number of males;

⁴In case of adalimumab;

⁵Abdominal pain, hair loss, fatigue, malaise, emotional instability;

⁶Testis carcinoma. NA: Not available.